SPONSORED CONTENT: As the biopharmaceutical landscape increasingly demands integrated technical operations, GCCs are expanding beyond back-office efficiency, reveals Shashidhar K L from Pivot Path.

As the divide between upstream output and downstream capability in bioprocessing expands, it is becoming necessary for the biopharma industry to address plant capacity, process intensification, digital connectivity, and business feasibility.

Experts from Alcami break down the latest innovations in lipid-based permeation matrices, continuous direct compression, and advanced analytical workflows designed to bring oral peptides to market safely and predictably.

From highly water-soluble APIs to the strict constraints of personalized therapies, masking unpleasant drug tastes remains a complex engineering challenge, requiring forward-thinking downstream strategies.

With an unprecedented patent cliff looming and complex modalities on the rise, executive teams must decouple capital investment risk from clinical uncertainty by embracing flexible, intensified manufacturing platforms.

Complex, targeted medicines are introducing bottlenecks into the CMC pathway, creating critical hurdles for clinical scale-up, emphasizes Henny Zijlstra from Ardena.

While DNA provides a baseline footprint for research and development, unlocking true biological complexity requires integrating dynamic multi-omics datasets, reveals Karolina Žukauskienė from VUGENE.

As pipelines shift toward complex, high-concentration, biological formulations, traditional manufacturing models are falling short, leading to a change in outsourcing strategies, notes Mark DaFonseca from Lifecore.

Ahead of BIO 2026, FUJIFILM Biotechnologies’ Toshi Iida outlines why the industry must pivot toward harmonized, modular facility networks to eliminate manufacturing bottlenecks and secure the global medicine supply.

As the drug development pipeline shifts toward complex biologics, traditional oral or frequent dosing regimens are being replaced by long-acting formulations, reveals David Westberg from Nanexa.

According to Sven Lee from Bionova, the era of predictable, plug-and-play bioprocessing platforms is coming to an end as novel advanced pipelines now require bespoke, early-stage intervention to ensure molecular quality.

Backed by USD 101 million in cumulative financing, Ethyreal Bio is targeting the shared pathogenic driver of Graves' disease and thyroid eye disease with a differentiated, long-acting subcutaneous antibody.

As the pharmaceutical supply chain digitizes, the unique human element of face-to-face networking remains fundamental, according to Sherma Ellis-Daal, Brand Director for CPHI Americas.

Ahead of CPHI Americas, Kent Payne from Wilmington PharmaTech reveals how shifting geopolitical regulations, private equity capital, and specialized technical expertise are driving domestic pharmaceutical manufacturing.

As the generic and biosimilar market enters a period of growth, developers are moving away from costly empirical testing and leveraging advanced technologies to overcome technical hurdles to formulation.

SPONSORED CONTENT: From AI-driven secondary packaging to enhanced business continuity, Timothy Compton outlines how Alcami is merging its legacy manufacturing excellence with new digital innovations to serve global markets.

Following the global launch of the Synchrony S1 PFS system, ten23 health has completed robustness testing to ensure the platform is ready for clients navigating the complexities of drug-device regulations.

With industry reaching the limits of traditional formulation techniques, to overcome solubility and bioavailability challenges, spray-drying is increasingly emerging as a primary development pillar.

As the industry pivots toward eco-design and green procurement, the whole value chain must align to bridge the gap between environmental targets and manufacturing reality.

As smaller batch products become more prominent within drug development, companies are being required to adopt more agile, modular approaches to ensure commercial viability is achievable.